TY - JOUR
T1 - Mixed connective tissue disease: State of the art on clinical practice guidelines
AU - Benjamin, Chaigne
AU - Carlo Alberto, Scirè
AU - Rosaria, Talarico
AU - Tobias, Alexander
AU - Zahir, Amoura
AU - Tadej, Avcin
AU - Lorenzo, Beretta
AU - Andrea, Doria
AU - Aurelien, Guffroy
AU - Vera, Guimarães
AU - Éric, Hachulla
AU - Thomas, Krieg
AU - David, Launay
AU - Gemma, Lepri
AU - Pia, Moinzadeh
AU - Ulf, M. ller-Ladner
AU - Simona, Rednic
AU - Ana, Rodrigues
AU - Tas, Sander W.
AU - van Vollenhoven, R. F.
AU - Ana, Vieira
AU - Stefano, Bombardieri
AU - Eurico, Fonseca João
AU - Ilaria, Galetti
AU - Matthias, Schneider
AU - Vanessa, Smith
AU - Maurizio, Cutolo
AU - Marta, Mosca
AU - Rebecca, Fischer-Betz
PY - 2018
Y1 - 2018
N2 - Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.
AB - Mixed connective tissue disease (MCTD) is a complex overlap disease with features of different autoimmune connective tissue diseases (CTDs) namely systemic sclerosis, poly/dermatomyositis and systemic lupus erythematous in patients with antibodies targeting the U1 small nuclear ribonucleoprotein particle. In this narrative review, we summarise the results of a systematic literature research which was performed as part of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases project, aimed at evaluating existing clinical practice guidelines (CPGs) or recommendations. Since no specific CPGs on MCTD were found, other CPGs developed for other CTDs were taken into consideration in order to discuss what can be applied to MCTD even if designed for other diseases. Three major objectives were proposed for the future development of CPGs: MCTD diagnosis (diagnostic criteria), MCTD initial and follow-up evaluations, MCTD treatment. Early diagnosis, epidemiological data, assessment of burden of disease and QOL aspects are among the unmet needs identified by patients.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055683332&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30402271
U2 - https://doi.org/10.1136/rmdopen-2018-000783
DO - https://doi.org/10.1136/rmdopen-2018-000783
M3 - Review article
C2 - 30402271
SN - 2056-5933
VL - 4
JO - RMD OPEN
JF - RMD OPEN
M1 - e000783
ER -